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The CCAAT/enhancer-binding protein  (C/EBP)
regulates a variety of factors and cellular responses
associated with pulmonary fibrosis. To distinguish its
role in the mesenchyme from that in other compart-
ments, the effects of mesenchymal-specific deletion
of C/EBP on pulmonary fibrosis was examined.
Crossing of mice with the floxed C/EBP gene with
2(I) collagen enhancer-CreER(T)-bearing mice
successfully generated progeny with a conditional
knockout (CKO) of C/EBP in collagen I-expressing
(“mesenchymal”) cells only on treatment with tamox-
ifen (C/EBP CKO). When treated with an endotracheal
bleomycin injection, C/EBP CKO mice showed signif-
icant attenuation of pulmonary fibrosis relative to con-
trol C/EBP-intact mice. C/EBP CKO mice also had
reducedmyofibroblasts in the lung. However, no signif-
icant differences in inflammatory/immune cell influx
were noted in the mutant mice relative to the control
mice. DNA microarray and real-time PCR analyses iden-
tified a series ofmyofibroblast differentiation regulators
as novel target genes of C/EBP. Interestingly, C/EBP
deficiency caused a marked induction of matrix metal-
loproteinase 12 expression, suggesting its potential role
as a repressor, which could account for the noted re-
duction in fibrosis in the C/EBP-deficient mice. Thus,
these findings indicate an essential role for C/EBP in
the mesenchymal compartment in pulmonary fibrosis
that is independent of its effects on inflammation or
immune cell infiltration. (Am J Pathol 2012, 180:2257–
2267; http://dx.doi.org/10.1016/j.ajpath.2012.02.010)
A key element in tissue repair and remodeling or fibrosis
is the mesenchymal response that provides the essential
extracellular matrix components for the infrastructure
necessary for healing on the one hand and chronic pro-
gressive fibrosis on the other hand.1 This response is a
result of mesenchymal cell activation, including differen-tiation into myofibroblasts.1–5 Myofibroblast differentia-
tion is characterized by induction of -smooth muscle
actin (-SMA; ACTA2) gene expression as well as by
increased expression of extracellular matrix components
and certain fibrogenic cytokines, such as transforming
growth factor .1–5 Because deposition of extracellular
matrix and release of fibrogenic cytokines are key factors
in perpetuating the cycle of injury and fibrosis, studies on
the regulation of myofibroblast differentiation may be of
value in elucidation of the basic mechanisms in the gen-
esis of chronic progressive fibroproliferative disease.
The essential role of CCAAT/enhancer binding pro-
teins (C/EBP) in regulating myofibroblast differentiation
and in fibrosis has been reported.6–9 C/EBP is one of
the basic region leucine zipper transcription factors10
and has two main isoforms, the liver-enriched activator
protein (LAP) and the N-terminal truncated isoform known
as liver-enriched inhibitor protein (LIP).8,9,11–13 LIP con-
tains the DNA binding domain of LAP but lacks its activation
domain.10 Both LAP and LIP bind to the C/EBP binding
consensus on the ACTA2 promoter.9 However, LAP acti-
vates ACTA2 gene expression, whereas LIP inhibits ex-
pression possibly through competition for binding.9
C/EBP plays important roles in fundamental cellular pro-
cesses, including cell proliferation, cell differentiation,
growth arrest, and apoptosis in a manner specific to
cell-type.9,14–17 During bleomycin-induced pulmonary fi-
brosis, multiple roles of C/EBP are identified in studies
that used C/EBP-null mice.8 The results show that defi-
ciency of C/EBP leads to attenuation of cytokine expres-
sion, decrease of myofibroblast differentiation, and in-
crease of fibroblast proliferation.8 Similar results are
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phosphorylation is suppressed.7 Despite this evidence of
an essential role for C/EBP in fibrosis, the specific un-
derlying mechanisms remain uncertain, given the pleth-
ora of target genes, biological processes, and cell types
regulated by this transcription factor. At least one possi-
ble mechanism is its importance in regulation of the
ACTA2 gene and thus myofibroblast differentiation.9
However, as noted above, C/EBP deficiency may also
affect inflammation,18 and perhaps other processes,
some of which may be related to the acute phase re-
sponse that is known to be regulated by this transcription
factor.18,19 Moreover, C/EBP is shown to be important in
regulating gene expression and function of lung epithelial
cells.20 Thus, the relative importance of these potential
mechanisms by which C/EBP regulates fibrosis requires
further elucidation. A possible strategy is to evaluate the
effect of selective C/EBP deficiency in certain cell types,
which have been made amenable by the availability of
Cre-lox technology.
Cre-ER(T) is a mutant of Cre recombinase originally
isolated from the P1 bacteriophage.21 It is a fusion pro-
tein comprising Cre and a mutated form of the ligand
binding domain of the estrogen receptor that renders Cre
activity tamoxifen inducible.21,22 This allows for condi-
tional modification of gene activity in the mammalian cells
by administration of tamoxifen because its binding to the
Cre recombinase activates its ability to excise DNA frag-
ments flanked by specific LoxP consensus sequences.22
If driven by a cell-specific promoter, this activity may be
localized to express only in that particular cell type. A
far-upstream enhancer of the 2(I) collagen gene has
been identified and found to be expressed mainly in
fibroblasts and other mesenchymal cells.23 The use of
this enhancer and associated promoter to drive the ex-
pression of Cre-ER(T) results in selective expression in
mesenchymal cells only when transgenic mice harboring
this construct are treated with tamoxifen.24
In this study, these transgenic Cre-ER(T) mice
[Col12-Cre-ER(T)/0] were used in conjunction with mice
(C/EBPfl/fl) harboring the floxed (containing loxP sites)
C/EBP (CEBPE) gene25 to distinguish the role of C/EBP
in the mesenchymal compartment from that in the inflam-
matory/immune system and other compartments. Cross-
ing these mice resulted in the generation of C/EBPfl/fl,
Col12-Cre-ER(T)/0 mice, which on treatment with ta-
moxifen caused a selective deficiency of C/EBP gene
expression only in all type I collagen-expressing cells (ie,
mesenchymal cells), and are referred heretofore as
C/EBP conditional knockout (CKO) mice. The C/EBP
CKO and control mice were then analyzed for their re-
sponsiveness to endotracheal bleomycin injection. The
results indicated significantly reduced fibrosis when
C/EBP was selectively knocked out in the mesenchymal
compartment, which was accompanied by reduction in
myofibroblast differentiation, whereas no significant ef-
fects were noted in inflammation or immune cell influx.
Further analysis showed that C/EBP deficiency in mes-
enchymal cells affected expression of a series of genes,
some of which are known to be regulators of myofibro-
blast differentiation. These findings indicated that unim-paired expression of C/EBP in the mesenchymal com-
partment was essential for pulmonary fibrosis.
Materials and Methods
Antibodies
The anti--SMA (catalog no. A2547) and anti-procollagen
I (catalog no. C2456) antibodies were purchased from
Sigma-Aldrich Co. (St. Louis, MO) and anti-C/EBP anti-
body (catalog no. SC150) was purchased from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA). Fluorescent-
labeled antibodies against CD3 (catalog no. 100219),
CD4 (catalog no. 130310), CD8 (catalog no. 100711),
B220 (catalog no. 103115), F4/80 (catalog no. 122609),
Gr-1 (catalog no. 108423), and E-cadherin (catalog no.
324113) for enumeration of T cells, CD4 and CD8 T
cells, B cells, macrophages, neutrophils, and epithelial
cells, respectively, were purchased from Biolegend Inc.,
San Diego, CA.
Animals
All animal protocols were approved by the University
Committee on Use and Care of Animals of the University
of Michigan. Mice with C/EBP coding region flanked
with LoxP recombination sites (C/EBPfl/fl) and mice car-
rying a tamoxifen-inducible Cre-recombinase [Cre-ER(T)]
under the control of a regulatory sequence from the 2(I)
collagen gene (C57BL/6J-Tg[Col12-Cre-ER(T)])24,25
were bred from breeding pairs, which were generous
gifts of Dr. Esta Sterneck (Molecular Mechanisms in De-
velopment Group, Laboratory of Protein Dynamics and
Signaling, National Cancer Institute, Frederick, MD) and
Dr. Benoit de Crombrugghe (Department of Genetics,
University of Texas M.D. Anderson Cancer Center, Hous-
ton, TX), respectively. Both strains were on a C57BL/6
background. To generate mesenchymal cell-specific
C/EBP-deficient mice, the C/EBPfl/fl mice were cross
bred with Col12-Cre-ER(T)/0 (heterozygous allele)
transgenic mice to generate mice heterozygous for both
alleles. The second cross between C/EBPfl/fl mice and
heterozygous mice from the first cross produced
C/EBPfl/fl, Col12-Cre-ER(T)/0 mice, which were used
for further experiments.
For treatment of mice, a stock solution of tamoxifen
(4-hydroxitamoxifen; Sigma-Aldrich Co.) in ethanol (100
mg/mL) was diluted in corn oil to 10 mg/mL. To selec-
tively delete C/EBP in mesenchymal cells, adult
C/EBPfl/fl, Col12-Cre-ER(T)/0 mice (8 weeks old) and
the relevant control [Col12-CreER(T)/0 with wild-type
C/EBP] mice were given daily intraperitoneal injections of
the tamoxifen suspension (0.1 mL of diluted stock) for 8
days to inducemesenchymal cell-specific expression of the
Cre-ER(T) recombinase and removal of the floxed C/EBP
coding region accordingly. The resultant C/EBP-deficient
mice were referred to as C/EBP CKO mice.
After the tamoxifen treatment regimen, the C/EBP CKO
and control mice were injected endotracheally with 2 U/kg
of body weight bleomycin (Blenoxane; Mead Johnson,
Princeton, NJ) dissolved in sterile PBS as before.8 The con-
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Daily tamoxifen treatment continued until the mice were
sacrificed at the indicated time points after bleomycin treat-
ment. Unless otherwise specified, two to five animals per
group were analyzed in each experiment.
All animals used for experiments were genotyped by
PCR to detect C/EBP and CreER(T) gene sequences as
described previously.24,25 For detection of the floxed
C/EBP by PCR in genotyping, the primer pairs used
were A with sequence (5=-GAGCCACCGCGTCCTC-
CAGC-3=) and B with sequence (5=-GGTCGGTGCGCGT-
CATTGCC-3=). For detection of the CreER(T) gene, the
following primers were used in genotyping: forward, 5=-
TCCAATTTACTGACCGTACACCAA-3=, and reverse, 5=-
CCTGATCCTGGCAATTTCGGCTA-3=.
Cell Culture
Mouse lung fibroblasts were isolated as described pre-
viously.9,26 The cells were cultured in Dulbecco’s modi-
fied Eagle’s medium supplemented with 10% plasma-
derived serum (Cocalico Biologicals, Reamstown, PA),
100 U/mL penicillin, 100 U/mL streptomycin, 0.25 U/mL
Fungizone, 1% insulin/transferrin/selenium (Sigma-Al-
drich Co.), 5 ng/mL platelet-derived growth factor (R&D
Systems, Minneapolis, MN), and 10 ng/mL epidermal
growth factor (R&D Systems) for 1 day. After removal of
the nonadherent cells by washing with PBS, the attached
cells were then cultured in complete medium as de-
scribed for three to five passages before analyses as
indicated. T cells from mouse spleens were isolated at
90% purity with the use of the CD3 Microbead Kit (Milte-
nyi Biotec Inc., Auburn, CA) in accordance with the man-
ufacturer’s protocol.
Morphologic Analysis
Morphologic analysis was performed as previous de-
scribed.8 Briefly, 21 days after the endotracheal injection of
saline or bleomycin, mice were euthanized, and the lungs
were thoroughly perfused with saline to remove blood from
the lung vascular beds. The lungs were then removed from
the thoracic cavity and fixed in formalin, followed by paraffin
embedding, sectioning, and staining with H&E.
Hydroxyproline Assay
To assess the extent of fibrosis, the collagen content of
whole lung homogenates was assayed by colorimetric
assay after acid hydrolysis as described previously.27
Western Blot Analysis
Western blot analysis was performed essentially as be-
fore.8 As indicated, homogenized murine lung tissue or
fibroblasts were lysed in radioimmunoprecipitation assay
protein lysis buffer that contained proteinase inhibitor
cocktail (Roche Diagnostics, Mannheim, Germany). After
determination of protein concentration by bicinchoninic
acid assay (Fisher Scientific, Pittsburgh, PA), equalamounts of total protein were electrophoresed through
12% SDS-polyacrylamide gels. The separated protein
bands were transferred onto Hybond P membranes and
blotted against different antibodies as indicated. Equal
loading was confirmed by reblotting the membrane with
horseradish peroxidase-conjugated anti-glyceraldehyde-3-
phosphate dehydrogenase antibody (catalog no. 9482)
from Abcam Inc. (Cambridge, MA). When indicated the
blots were scanned and digitized, and the band intensities
were quantified with the use of Carestream Molecular Im-
aging software V.5.0.2.30 (Carestream Health, Inc., Roch-
ester, NY).
mRNA Analysis
Determination of mRNA for the indicated genes was per-
formed with the use of real-time PCR as before.8 With this
method, a CT value reflects the cycle number at which
DNA amplification is detected.28 The amount of target,
normalized to endogenous reference and relative to a
calibrator, is given by 2CT.28 Total RNA was extracted
from either murine lung tissue or fibroblasts as indicated.
For each assay, 200 ng of total RNA was used as tem-
plate and 18S rRNA was used as internal control to nor-
malize the amount of input RNA. One-step real-time RT-
PCR (48°C for 30 minutes, 95°C for 10 seconds, followed
by 50 cycles at 95°C for 10 seconds, 60°C for 1 minute)
was performed with Taqman One Step RT-PCR Master
Mix with the use of a GeneAmp 7500 Sequence Detection
System (Applied Biosystems Inc., Foster City, CA). Prim-
ers and probes were purchased from Applied Biosys-
tems Inc.
Flow Cytometric Analysis
Whole lung cell suspensions were prepared by digesting
the lungs from C/EBP CKO mice and wild-type control
mice after bleomycin or saline injection at indicated time
points with collagenase and DNase digestion mixture [5
mg of collagenase and 1 mg of DNase (Worthington
Biochemical Co., Lakewood, NJ) in 10 mL of Hank’s
Buffered Salt Solution supplemented with 1 mL of plas-
ma-derived serum] for 1.5 hours at 37°C. The suspen-
sions were then filtered with 100-m and 40-m mesh
cloth and washed with 1 PBS. The cell suspensions
were then fixed with 4% paraformaldehyde in 1 PBS
and stained with fluorescent-labeled specific primary an-
tibody of interest or corresponding IgG control in 1 PBS
only or 1 PBS containing 0.1% saponin (for staining of
intracellular proteins) for 1 hour at room temperature.
After stringent washing, they were analyzed on a Becton-
Dickinson LSR-II machine (BD Biosceinces, Chicago, IL).
Data collected were then analyzed with the use of FlowJo
flow cytometric analysis software V.7.6.5 (TreeStar Inc.,
Ashland, OR). For evaluation of inflammatory/immune re-
sponse, the whole lung cell suspension was stained with
fluorescent-labeled antibodies against CD3, CD4, CD8,
B220, F4/80, and Gr-1 for enumeration of T cells, CD4
and CD8 T cells, B cells, macrophages, and neutro-
phils, respectively.29–32 To evaluate the expression of
C/EBP, the lung cell suspensions were stained with
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minutes, and washed twice with 1 PBS. They were
further stained with anti-C/EBP antibody and analyzed
by flow cytometry.
cDNA Microarray Analysis
cDNA microarray analysis was performed essentially as
previously described.33 Mouse lung fibroblasts were iso-
lated from either C/EBP CKO mice (N  3) or the cor-
responding control mice (N  3) treated with either bleo-
mycin or saline. The total RNAs from each group were
then extracted with Tryzol reagent (Invitrogen Co., Carls-
bad, CA) and labeled with fluorescent dyes. The total
RNAs were hybridized to GeneChip mouse genome
430A 2.0 (part no. 900499; Affymetric, Inc., Santa Clara,
CA) at 65°C overnight. Fluorescent images were ob-
tained with the use of a GenePix 4000B microarray scan-
ner (Axon Instruments, Foster City, CA) and analyzed
with the GenePix software package v.7 (Axon Instru-
ments, Foster City, CA). Briefly, some quality control plots
were checked to confirm the overall quality of the raw
data. The potential differences between samples caused
by mRNA degradation or in vitro translation were pre-
cluded. The distribution of each chip was analyzed in a
way that all of the data come from the same distribution
with the only differences being the location and scale.
The expression values for each gene were then calcu-
lated with the use of a robust multiarray average method
developed by Irizarry et al,34 which is a modeling strat-
egy that converts the probe values into log2-transformed
expression value for each gene. Genes that show greater
than twofold difference between the C/EBP CKO cell
and control cell samples were shown in a heat map
generated with the Heatmap builder program.35 The
gene ontology analysis was done with the DAVID Func-
tional Annotation Bioinformatics Microarray Analysis on-
line (http://david.abcc.ncifcrf.gov) according to their in-
struction.Statistical Analysis
Statistical analysis was performed as before with the use
of analysis of variance, followed, when appropriate, by
post hoc testing with Scheffé’s test.8 A P value  0.05
was used as a criterion for statistical significance in com-
parisons between any two groups.
Results
Generation of Mice with Selective Deficiency
of C/EBP in the Mesenchymal Compartment
(C/EBP CKO mice)
C/EBP homozygous floxed mice (C/EBPfl/fl) with
C/EBP coding region flanked with LoxP recombination
sites were cross bred with mice harboring a CreER(T)
recombinase gene located downstream of a 2(I) colla-
gen promoter/enhancer and then back crossed with the
C/EBPfl/fl mice to obtain mice homozygous for the floxed
C/EBP allele and hemizygous for the Col12-Cre-ER(T)
allele with genotype [C/EBPfl/fl, Col12-Cre-ER(T)/0].
These mice were verified for genotype with PCR analysis
of genomic DNA from tail tissue samples, which showed
the correct expression of either wild-type or floxed
C/EBP (Figure 1A), and CreER(T) (Figure 1B). After ver-
ification, the appropriate mice were then treated with
tamoxifen as described inMaterials and Methods to delete
the C/EBP gene in the mesenchymal compartment only
and were referred to as C/EBP CKO mice. The loss of
C/EBP expression in the mesenchymal compartment of
C/EBP CKO mice was evaluated in lung fibroblasts iso-
lated from both saline- or bleomycin-treated C/EBP
CKO mice and control mice [C/EBP/, Col12-Cre-
ER(T)/0], which bore the same CreER(T) gene but the
wild-type C/EBP gene. Western blot analysis of protein
samples from these cells found the expected C/EBP
protein isoforms in lung fibroblast samples from control
Figure 1. Mouse genotype analysis. A: PCR am-
plification of the C/EBP gene. Mouse genomic
DNA was extracted and mixed with PCR primers
specific for the C/EBP gene. The PCR products
and 100-bp ladder (NEB) were separated in a
1.3% agarose gel and photographed. The
240-bp DNA fragment expected for the
C/EBP allele and an 300-bp DNA fragment
expected for the C/EBPfl allele are indicated. B:
The same genomic DNA samples were used
with PCR primers specific for the CreER(T) gene.
The PCR products were separated by agarose gel
electrophoresis as above. The 500-bp ampli-
fied CreER(T) gene fragment is indicated.mice, but which were virtually totally absent in those from
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mice C/EBP expression was intact in T cells (Figure 2B)
and other cells not expressing type I collagen (see Sup-
plemental Figure S1 at http://ajp.amjpathol.org), thus con-
firming the selective deficiency of C/EBP expression
only in the mesenchymal compartment. Deficiency of
C/EBP in the CKO mice was accompanied by some
reduction in -SMA expression in lung fibroblast samples
from animals treated with saline and bleomycin (Figure
2A). The reduced -SMA protein levels in the C/EBP-
deficient cells were significantly less in both cases (P 
0.05) relative to their respective saline controls when the
blots were digitized and quantitated.
Reduced Fibrotic Response in C/EBPCKOMice
Although C/EBP is known to be essential for fibrosis,6–9
its precise role is uncertain, given its pleiotropic effects in
diverse cell types and biological processes.8,19,20 To nar-
row the possibilities would require examination of its role
in specific cell types involved in the fibrotic process.
Thus, the feasibility of producing C/EBP CKO mice was
exploited to study the effect of selective deficiency of
C/EBP in the mesenchymal compartment on the bleo-
mycin model of pulmonary fibrosis. Because the C/EBP
CKO mice had the floxed C/EBP gene and the Col12-
CreER(T) transgene, as well as being generated by in-
jection of tamoxifen, several options for control mice had
to be considered. Myofibroblast differentiation as mea-
Figure 2. Confirmation of C/EBP deficiency in the mesenchymal compart-
ment. C/EBP CKO mice with genotype [C/EBPfl/fl, Col12-Cre-ER(T)/0]
and control mice with genotype [C/EBP/, Col12-Cre-ER(T)/0] were
pretreated for 8 days with tamoxifen and then separated into two groups for
each genotype. One group was injected endotracheally with bleomycin and
the other group with PBS. Tamoxifen treatment was continued daily after the
bleomycin/PBS injection until the mice were sacrificed 14 days after the
bleomycin injection. A: Lung fibroblasts from these mice were analyzed for
-SMA and C/EBP proteins by Western blot analysis. Mice (N  4) were
tested, and a representative blot from two mice is shown. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was used as loading control. B: Pro-
tein extracts of splenic T cells and lung fibroblasts from tamoxifen-treated
C/EBP CKO and control mice were analyzed for C/EBP protein isoforms
by Western blot analysis. Mice (N  4) were tested, and a representative blot
is shown with GAPDH used for loading control.sured by -SMA expression was selected for evaluationof the suitable control mice because it is a known C/EBP
target gene in the mesenchymal compartment.8,9 Thus,
lung tissue extracts from mice with the genotypes of
C/EBPfl/fl, [C/EBPfl/fl, Col12-Cre-ER(T)/0], and Col12-
Cre-ER(T)/0 were analyzed for -SMA protein by Western
blot analysis to see if any of these genotypic modifications
would affect myofibroblast differentiation. Tamoxifen
treatment alone was noted to reduce lung tissue -SMA
protein levels in all murine strains (Figure 3). However,
among the tamoxifen-treated groups lung -SMA expres-
sion was not significantly different between the mice with
the indicated three different genotypes. Thus, the mice
with genotype ([C/EBP/, Col12-Cre-ER(T)/0], in-
jected with tamoxifen) was selected as the control mice
for the C/EBP CKO mice to obtain a genotype as similar
as possible to the CKO mice.
After tamoxifen treatment to generate the C/EBP CKO
and control mice, the mice were then analyzed for re-
sponsiveness to bleomycin-induced pulmonary fibrosis.
Morphologically the lungs from saline-treated control and
C/EBP CKO mice did not exhibit any significant pathol-
ogy and were indistinguishable (Figure 4, A and E versus
C and G, respectively). In response to bleomycin treat-
ment, the expected pattern of fibrosis was seen in the
control mice with extensive distortion of the normal alve-
olar architecture characterized by increased thickness of
alveolar septa, inflammatory cell infiltration, increased
number of fibroblasts, and interstitial collagen deposition
(Figure 4, B and F). However, lungs of bleomycin-treated
C/EBP CKO mice exhibited much smaller areas of fibro-
sis that were sparsely distributed (Figure 4, D and H)
relative to those seen in the control mice and exhibited
more normal areas of intact lung. Thus, histopathologi-
cally evidence was seen of reduced pulmonary fibrosis in
the mice with selective deficiency of C/EBP in the mes-
enchymal compartment.
To further characterize this effect quantitatively, total
lung tissue hydroxyproline content was analyzed as a
measure of lung collagen deposition on day 21 after
bleomycin or saline treatment. In saline-treated mice,
C/EBP deficiency did not significantly affect lung hy-
droxyproline content (Figure 5A) or type I collagen pro-
tein levels (Figure 5B), but it did cause a significant
reduction in lung type I collagen mRNA (Figure 5C). The
results also showed that bleomycin treatment caused the
expected significant increase in lung hydroxyproline con-
tent in control mice (Figure 5A), but which was signifi-
cantly reduced by 50% in the C/EBP CKO mice (69%
Figure 3. Effects of Cre and tamoxifen on -SMA expression. Mice with the
indicated genotypes were injected with tamoxifen or vehicle only as indi-
cated. The lungs were then removed and homogenized to obtain protein
extracts for analysis of -SMA protein by Western blot analysis. Mice (N  4)
were tested, and a representative blot is shown with glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as the loading control.
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spectively). This significant reduction in the bleomycin-
induced increase in lung collagen deposition in C/EBP
CKO mice was also reflected in lung type I collagen
expression analyzed at the protein and mRNA levels.
Thus, Western blot analysis of lung protein extracts found
a much reduced bleomycin-induced increase in type I
collagen protein levels in these mice compared with the
vigorous response in control mice (Figure 5B). This re-
duction in responsiveness to bleomycin treatment was
similarly noted for lung -SMA protein levels. Analysis of
lung type I collagen mRNA found similar differences be-
tween these two strains of mice (Figure 5C). Thus, selec-
tive loss of C/EBP expression in the mesenchymal com-
partment caused a significant reduction in pulmonary
fibrosis in this animal model.
Reduction of Myofibroblasts in C/EBP
CKO Mice
Myofibroblast differentiation is regulated by C/EBP with
Figure 4. Effect of mesenchymal C/EBP deficiency on bleomycin-induced
lung histopathology. Tamoxifen-treated C/EBP CKO mice were given en-
dotracheal injections of either bleomycin or saline, and 21 days later lung
tissue sections were stained with H&E. Representative sections from control
mice treated with saline (A and E) or bleomycin (B and F) and from C/EBP
CKO mice treated with saline (C and G) or bleomycin (D and H) are shown.
Original magnification: 10 (A–D); 40 (E–H). Scale bars are included in
each panel.ACTA2 being one of its target genes.8,9 Thus, the notedreduction in bleomycin-induced increase in C/EBP CKO
lung -SMA protein content (Figure 5B) would be consis-
tent with those prior observations. To confirm the protein
analysis, the number of lung -SMA-expressing cells was
analyzed by flow cytometry after dissociation of the lung
tissue samples into single-cell suspensions. The results
showed a greater than threefold bleomycin-induced in-
crease in lung -SMA-positive cells in control mice (Fig-
ure 6A). This bleomycin-induced effect was significantly
blunted in C/EBP CKOmice, which exhibited a less than
twofold increase. Further analysis of lung -SMA mRNA
by real-time PCR found small but statistically insignificant
reductions in lung tissue and fibroblast levels (Figure 6, B
and D, respectively) in samples from saline-treated
C/EBP CKO mice relative to those in saline-treated con-
trol mice. However, significant reduction in bleomycin-
Figure 5. Effect of mesenchymal C/EBP deficiency on bleomycin-induced
lung collagen deposition. Mice (N  5 per group) were treated with saline or
bleomycin after tamoxifen injection for 7 (real-time PCR analysis) or 21
(hydroxyproline assay and Western blot analysis) days. The lungs were
harvested and analyzed for hydroxyproline content (A), type I collagen and
-SMA protein levels (B), and type I collagen mRNA levels (C). A: Results are
expressed as a percentage of the respective saline control values and shown
as mean 	 SE (N  5). *P  0.05. B: Each lane represents a single animal.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a load-
ing control after stripping the membrane. Only samples from three of the five
animals are shown. Similar results were obtained from the remaining two
animals (not shown). C: 1(I) procollagen mRNA was detected by real-time
PCR, and the results are expressed as 2CT, with 18S rRNA used as the
reference and the level in saline-treated wild-type mice used as calibrator.
Data are shown as mean 	 SE from triplicate samples. *P  0.05 bleomycin-
treated group compared with saline control; **P  0.05 relative to the
saline-treated mice with control genotype.
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in control mice was noted for lung tissue -SMA mRNA
(Figure 6B). Moreover, when lung fibroblasts were iso-
lated from these mice, their -SMA mRNA levels exhib-
ited similar changes. Thus, lung fibroblasts from bleomy-
cin-treated control mice showed a fourfold increase in
-SMA mRNA compared with those from saline-treated
control mice, whereas the comparable cells from the
C/EBP CKO mice exhibited only a twofold increase (Fig-
ure 6C). When these fibroblasts were treated in vitro with
transforming growth factor , a known inducer of myofi-
broblast differentiation, the expected induction of -SMA
expression was significantly reduced in the cells from
C/EBP CKO mice relative to that seen in cells from
wild-type mice (Figure 6D). Thus, attenuated fibrosis was
associated with reduction in lung myofibroblast differen-
tiation in mice selectively deficient in C/EBP expression
in the mesenchymal compartment.
Loss of C/EBP in the Mesenchymal
Compartment Does Not Affect Inflammation
Endotracheal injection of bleomycin incites acute and
chronic inflammation.36 In view of the role of C/EBP in
regulation of the inflammatory and acute phase re-
sponses, the effect of C/EBP deficiency in the mes-
enchymal compartment on the inflammatory response
to bleomycin was also evaluated. Analysis of whole
lung cell suspensions by flow cytometry found the ex-
pected bleomycin-induced increases in the number of
inflammatory and immune cells at day 7 after bleomy-
cin treatment (Figure 7). At this time point the increase
in neutrophils was beginning to decline, whereas the
increase in mononuclear cells, including macrophagesand T lymphocytes, were significant in the control
mice. These bleomycin-induced increases in cells
were not significantly different in the C/EBP CKO
mice, whereas the numbers of B lymphocytes were not
significantly affected by bleomycin treatment at this
time point. Thus, selective deficiency of C/EBP in the
mesenchymal compartment had no significant effect
on the inflammatory response in response to bleomy-
cin-induced lung injury.
Figure 6. Effect of mesenchymal C/EBP defi-
ciency on bleomycin-induced lung myofibro-
blast differentiation. Mice were treated with sa-
line or bleomycin after tamoxifen injection for 7
(real-time PCR analysis) or 21 (flow cytometry
and Western blot analysis) days, and the lung
samples were harvested for analysis of myofi-
broblast differentiation. A: Single-cell suspen-
sions were obtained from lung tissue by enzy-
matic digestion and analyzed for -SMA-positive
cells by flow cytometry. The results were ex-
pressed as the percentage of -SMA-positive
cells in the total lung cell suspension. B: Lung
tissue RNA samples were analyzed for -SMA
mRNA by real-time PCR. C: Similar analyses of
-SMA mRNA were performed for lung fibro-
blasts isolated from lungs of mice treated as in A
and B. D: Mouse lung fibroblasts were isolated
from either C/EBP CKO or wild-type mice.
They were treated with 4 ng/mL transforming
growth factor (TGF) for 48 hours, and the
mRNAs were analyzed by real-time PCR. The
mRNA results were expressed as 2CT, with
18S18S rRNA used as the reference and the level
in saline-treated control mice (A–C) or buffer-
treated wild-type cells (D) used as calibrator.
Data are shown as mean 	 SE from triplicate
samples. *P  0.05 versus saline-treated controls
(A–C) and TGF-treated wild-type cells (D).
Figure 7. Effect of mesenchymal C/EBP deficiency on bleomycin-induced
lung inflammation. Single-cell suspensions were prepared from the lungs of
tamoxifen-treated C/EBP CKO and control mice receiving endotracheal
injection of either bleomycin or saline as indicated. Seven days later, the lung
samples were analyzed for the indicated inflammatory/immune cells by flow
cytometry, and data were expressed as the percentage of total cells in the
suspension. Data are shown as mean 	 SE from five mice in each group.
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gene expression. Lung fibroblasts were isolated from C/EBP CKO and
control mice treated with either bleomycin or saline for 7 days as indicated
after the tamoxifen treatment regimen. Extracts of RNA were then subjected
to DNA microarray analysis (A) or real-time PCR analysis (B). A: The
expression values for each gene were calculated with a robust multiarray
average method that converted the probe values into log2-transformed
expression value for each gene. Genes that showed a greater than twofold
difference in DNA microarray analysis between the C/EBP CKO cell versus
control cell samples (N  1) are shown as a heat map in order of dimin-
ishing differences toward the center (vertically). Color intensity is scaled
within each row so that the highest expression value corresponds to bright
red and the lowest to bright green. The sample identifiers are listed on the
top of each column, and the gene names are listed to the right. B: Total RNA
samples from the cells were analyzed for the indicated mRNA species by
real-time PCR. The 18S rRNA was used as reference, and the saline-treated
wild-type control was used as calibrator for each gene in calculation of
2CT. Data are shown as mean 	 SE, with N  3. *P  0.05 versus
wild-type control.
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and Gene Expression
C/EBP binding to its binding consensus in the ACTA2
gene promoter regulates ACTA2 gene expression and
myofibroblast differentiation.9 To investigate its role in
expression of other genes that affect myofibroblast func-
tion and differentiation, the effect of this selective C/EBP
deficiency on lung fibroblast gene expression was eval-
uated with the use of microarray analysis. The results
showed 100 genes whose expression was altered
greater than twofold in fibroblasts as a consequence of
the loss of C/EBP gene expression (Figure 8A; see also
Supplemental Table S1 at http://ajp.amjpathol.org). A
subset of genes was identified with well-established roles
in the regulation of myofibroblast differentiation and func-
tion, such as matrix metalloproteinase 12 (MMP12), phos-
phatase and tensin homolog deleted on chromosome 10
(PTEN), DNA methyltransferase 3a (DNMT3a), and
(Kruppel-like factor 4 (KLF4), whose expression was up-
regulated by C/EBP deficiency. The increased expres-
sion in these genes was confirmed by real-time PCR,
which found that, among these genes, the marked induc-
tion of MMP12 (greater than fivefold increase relative to
cells from control mice) in cells from CKO mice was
highest in amplitude (Figure 8B). In addition, the relative
(to cells from saline-treated mice) increase in PTEN and
decrease in MMP12 expression in cells from bleomycin-
treated control mice was not seen in the comparable cells
from CKO mice.
Discussion
C/EBP is a multifaceted trans-acting factor that can play
diverse roles in regulation of cell proliferation, differenti-
ation, and apoptosis.10 In bleomycin-induced pulmonary
fibrosis, C/EBP activity is implicated in the regulation of
lung cytokine expression, myofibroblast differentiation,
and collagen deposition according to studies that used
C/EBP knockout mice.8 However, phenotypes of germ-
line knockouts can be complicated by pleiotropic effects
of the gene of interest in various tissues and organs
through multiple mechanisms. Thus, the use of such
knockout mice would not allow distinction between the
various possible mechanisms or roles of the targeted
gene. In the specific instance of C/EBP, it is impossible
to distinguish effects on the fibroblasts versus epithelial
or inflammatory cells with the use of such knockout mice.
To begin to address this issue, in this study the objective
was to evaluate the effect of selective deficiency in the
mesenchymal compartment on pulmonary fibrosis to dis-
tinguish from effects on the epithelial or inflammatory
compartment. This was achieved by conditional expres-
sion of the Cre recombinase in collagen I-expressing
cells on treatment with tamoxifen to knockout C/EBP
only in those cells, while leaving it intact in epithelial and
inflammatory cells that do not express collagen I. These
conditional collagen I-driven Cre expressing mice have
been previously used in mesenchymal cell-specificknockout of other target genes of interest and showed no
significant effects of Cre expression in these cells.37,38
Comparison of lung tissue and cells from the C/EBP
CKO mice with those from control mice found slight de-
creases in the expressions of type I collagen (COL1A)
and -SMA, (ACTA2) both of which are known C/EBP
target genes.8,9,39 Under these “basal” conditions,
C/EBP would not be expected to be induced, which
could explain the noted slight decrease in target gene
expression because of deficiency of this transcription
factor. No significant differences were observed for lung
immune/inflammatory cell composition as a result of se-
lective mesenchymal cell C/EBP deficiency in saline-
treated mice. However, notable significant increases in a
number of genes (PTEN, KLF4, DNMT3a, and MMP12)
were detected in the deficient mice, which may reflect a
novel repressor role for C/EBP on these genes. Overall,
mesenchymal cell C/EBP deficiency caused relatively
minor changes in the basal expression of type I collagen
and -SMA genes, which are known to be activated by
this transcription factor. This selective deficiency, how-
ever, caused a greater effect basally on genes that ap-
peared to be repressed by C/EBP. However, develop-
mentally and with respect to lung structure, this cell-
selective deficiency did not cause any detectable
abnormalities.
However, when these mesenchymal-specific condi-
tional C/EBP knockout mice were studied with the use of
the bleomycin model, wherein C/EBP is induced, the
results indicated that mesenchymal-specific loss of
C/EBP resulted in significant reduction of bleomycin-
induced lung myofibroblast differentiation. This would be
consistent with previous studies in which full-length
C/EBP is shown to enhance myofibroblast differentia-
tion.8,9 Because myofibroblasts are the main source of
fibrogenic cytokine and extracellular matrix gene expres-
sion,2,3 loss of the myofibroblast in the C/EBP CKOmice
would be expected to result in reduced fibrosis. This was
indeed the case as evidenced by both histopathologic
evaluation as well as quantitative biochemical analysis of
lung collagen deposition. Further evidence was obtained
by analysis of collagen gene expression, which found
significantly reduced levels of collagen I mRNA.
In addition to these effects of C/EBP on mesenchymal
cells, it is also known to be a regulator of the inflammatory
response, including the acute phase response,18,19
which may also affect pulmonary fibrosis via indirect
mechanisms (in contrast to directly affecting matrix-pro-
ducing mesenchymal cells). The C/EBP CKO mice ex-
hibited normal levels of C/EBP expression in inflamma-
tory/immune as well as lung epithelial cells, thus
confirming specific knockout only in the mesenchymal
compartment. Moreover, bleomycin-induced lung inflam-
matory/immune cell recruitment was essentially unim-
paired in these CKO mice. Thus, impairment of pulmo-
nary fibrosis in mice lacking C/EBP expression in the
mesenchymal compartment only was not due to effects
on the inflammatory/immune cell recruitment. Moreover, it
was also independent of C/EBP-regulated genes in the
epithelial compartment. The evidence thus supports the
conclusion that the observed effects of specifically elim-
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mainly mediated through the regulation of myofibroblast
differentiation and perhaps other C/EBP target genes in
lung fibroblasts.
In the search for other potentially relevant C/EBP tar-
get genes, microarray analysis was performed, which
found multiple gene candidates whose expression was
significantly altered by C/EBP deficiency. These genes
included components of Wnt, IL-1, and IL-13 signaling
pathways; cell differentiation; and proliferation regulators,
as well as extracellular cell matrices and chemokine re-
ceptors. Transcription factors with known regulatory ac-
tivity on the ACTA2 promoter affected by C/EBP defi-
ciency were also identified. For example, C/EBP
deficiency increased expression of KLF4, a repressor of
myofibroblast differentiation through binding to the TGF
control element in the ACTA2 gene promoter and through
interaction with Smad3.40–42 Similar stimulatory effects
on expression of PTEN and DNMT3a were also evident in
the absence of C/EBP. Both of those genes are known
to be negative regulators of myofibroblast differentia-
tion.43,44 In the case of PTEN, its expression is signifi-
cantly diminished in idiopathic pulmonary fibrosis lung
myofibroblasts within fibroblastic foci relative to control
lung fibroblasts.44 DNMT3a catalyzes de novo DNAmeth-
ylation of cytosine phosphate guanine (CpG) islands and
was shown to directly affect methylation of ACTA2 gene
sequences that resulted in repression of ACTA2 gene
expression.43 Thus, in addition to direct negative effects
on ACTA2 gene expression, C/EBP deficiency could
potentially suppress fibrosis by enhancing expression of
these two known suppressors of myofibroblast differenti-
ation. Another potential candidate target gene of interest
is MMP12, which was markedly induced in the absence
of C/EBP. Some evidence suggests a role for MMP12 in
fibrosis.45–47 However, the potential mechanism here
would be different and probably independent of effects
on myofibroblast differentiation from the standpoint of
ACTA2 gene expression. In view of its matrix-degrading
activity, its overexpression would be expected to result in
reduced fibrosis and matrix deposition, which was in-
deed the case in the bleomycin model from this study, as
well as in a previous report in IL-13-dependent emphy-
sema.48 Other potential candidate genes remain to be
analyzed and will be the subject of future studies. Thus, in
addition to directly affecting the ACTA2 promoter activ-
ity,9 C/EBP may also regulate myofibroblast differentia-
tion indirectly through mediation by other regulators of
ACTA2 gene expression and/or MMP12 expression.
In conclusion, the findings in this study for the first time
show the specific importance of C/EBP expression in
the mesenchymal compartment in pulmonary fibrosis.
The mechanism likely involved multiple C/EBP target
genes with effects on diverse pathways of regulatory
importance to myofibroblast differentiation, extracellular
matrix production, deposition, and degradation. Although
the results confirmed the importance of mesenchymal
C/EBP expression on myofibroblast differentiation in
vivo, they did not rule out the contribution of the inflam-
matory/immune and epithelial compartments. These con-
tributions are suggested by the incomplete suppressionof fibrosis by the absence of C/EBP in the mesenchymal
compartment. Additional future studies are warranted to
more precisely examine this contribution by the nonmes-
enchymal compartments.
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